Research Nester published a report titled Duchenne Muscular Dystrophy Treatment Market: Global Demand Analysis & Opportunity Outlook 2030” which delivers detailed overview of the global Duchenne muscular dystrophy treatment market in terms of market segmentation by therapy, treatment, distribution channel, and by region.

Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.

The global Duchenne muscular dystrophy treatment market is estimated to grow at a CAGR of ~11% over the forecast period, i.e., 2022 – 2030. The market is segmented on the basis of treatment into corticosteroids, pain management drugs, physical therapy, and others. Out of which, the pain management drugs segment is anticipated to hold the largest revenue share over the forecast period owing to the high demand for pain management drugs, as Duchenne muscular dystrophy can be extremely painful.

Get a Sample PDF Brochure:

The global Duchenne muscular dystrophy or DMD treatment market is anticipated to grow on the back of increasing cases of genetic muscle-related disorders, backed by poor lifestyle of majority of the population. According to the data by the World Health Organization (WHO), over 1.71 billion people suffer from musculoskeletal disorders across the world. Furthermore, the high share of male population globally, is estimated to propel the market growth, as DMD is more prevalent in males. According to the data by the National Organization of Rare Disorders (NORD), 1 in every 3,500 male suffers from DMD. Moreover, the growing demand for treatment method, and increasing research activities for development of efficient treatment are estimated to boost the market growth.

On the basis of geographical analysis, the global Duchenne muscular dystrophy treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in the North America region is anticipated to gain the largest market share throughout the forecast period on account of the high health awareness amongst the population. Moreover, high investment in R&D activities, and presence of major market players in the region.

The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players’ competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.

Browse full report summary :

High Global Male Population to Boost the Market Growth

According to the statistics by the World Bank, in 2020, 50.415% of the global population was male.

Duchenne muscular dystrophy is a progressive inherited muscular disease, which is highly prevalent amongst men. This is why, the high male population across the globe is estimated to boost the market growth. Moreover, increasing research and development activities in the healthcare industry is estimated to propel the market growth.

However, complicated and difficult diagnosis of DMD, and lack of health awareness amongst underdeveloped region are expected to operate as key restraint to the growth of global Duchenne muscular dystrophy treatment market over the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global Duchenne muscular dystrophy treatment market which includes company profiling of Eli Lilly and Company, Novartis AG, Sanofi-aventis Groupe, Abbott Laboratories, Johnson & Johnson Services, Inc., Merck & Co., Inc., Siemens Healthcare GmbH, and Pfizer Inc. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global Duchenne muscular dystrophy treatment market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

Request Report Sample@

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: [email protected]

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *